Sunil S Badve
Overview
Explore the profile of Sunil S Badve including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
3946
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rakha E, Quinn C, Raymond W, Allison K, Badve S, Brogi E, et al.
Mod Pathol
. 2025 Feb;
38(5):100734.
PMID: 39947480
Fibroepithelial lesions (FELs) of the breast represent a diverse group of biphasic tumors with varying morphologies and clinical behavior. The classification of FELs is mainly based on a constellation of...
2.
Khemka A, Clasen S, Loehrer P, Roberts A, Golzarri-Arroyo L, Badve S, et al.
Front Cardiovasc Med
. 2024 Sep;
11:1393631.
PMID: 39346095
Introduction: Cancer patients may have increased risk for adverse cardiac events, but our understanding of cardiovascular risk in thymic cancer patients is not clear. We sought to characterize baseline cardiometabolic...
3.
MorphLink: Bridging Cell Morphological Behaviors and Molecular Dynamics in Multi-modal Spatial Omics
Huang J, Yuan C, Jiang J, Chen J, Badve S, Gokmen-Polar Y, et al.
bioRxiv
. 2024 Sep;
PMID: 39253421
Multi-modal spatial omics data are invaluable for exploring complex cellular behaviors in diseases from both morphological and molecular perspectives. Current analytical methods primarily focus on clustering and classification, and do...
4.
Sparano J, Crager M, Gray R, Tang G, Hoag J, Baehner F, et al.
NEJM Evid
. 2024 Jul;
3(8):EVIDoa2300267.
PMID: 39041867
Background: The 21-gene recurrence score (RS) assay (Oncotype DX) is used to guide adjuvant chemotherapy use for patients with hormone receptor-positive, HER2 (human epidermal growth factor receptor 2)-negative, axillary node-negative...
5.
Li H, Aggarwal A, Toro P, Fu P, Badve S, Cuzick J, et al.
Lancet Digit Health
. 2024 Jul;
6(8):e562-e569.
PMID: 38987116
Background: The density of tumour-infiltrating lymphocytes (TILs) could be prognostic in ductal carcinoma in situ (DCIS). However, manual TIL quantification is time-consuming and suffers from interobserver and intraobserver variability. In...
6.
Geurts V, Balduzzi S, Steenbruggen T, Linn S, Siesling S, Badve S, et al.
JAMA Oncol
. 2024 Jun;
10(8):1077-1086.
PMID: 38935352
Importance: The absolute benefit of chemotherapy for all patients with stage I triple-negative breast cancer (TNBC) is unclear, and biomarkers are not currently available for selecting patients with an excellent...
7.
Keskinkilic M, Gokmen-Polar Y, Badve S
Clin Breast Cancer
. 2023 Nov;
24(1):1-6.
PMID: 38016912
Triple negative breast cancer is defined on the basis of what it is not. It has served as a useful umbrella entity for management of patients with breast cancer for...
8.
Turashvili G, Gjeorgjievski S, Wang Q, Ewaz A, Ai D, Li X, et al.
Breast Cancer Res Treat
. 2023 Sep;
202(3):423-434.
PMID: 37688667
Purpose: Although axillary dissection is no longer indicated for many breast cancer patients with 1-2 positive axillary sentinel lymph nodes (ASLN), intraoperative ASLN assessment is still performed in many institutions...
9.
Badve S, Gokmen-Polar Y
Expert Opin Ther Targets
. 2023 Jul;
27(6):447-457.
PMID: 37395003
Introduction: Cancer development and progression is a complex process influenced by co-evolution of the cancer cells and their microenvironment. However, traditional anti-cancer therapy is mostly targeted toward cancer cells. To...
10.
Robert M, Ruschoff J, Jasani B, Graham R, Badve S, Rodriguez-Justo M, et al.
Mod Pathol
. 2023 Jun;
36(7):100238.
PMID: 37327723
No abstract available.